{"organizations": [], "uuid": "48628716ab2cba3963c880fa6cca757517e434a1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180213.html", "section_title": "Archive News &amp; Video for Tuesday, 13 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-ipsen-biopharmaceuticals-canada-sa/brief-ipsen-biopharmaceuticals-canada-says-health-canada-approved-somatuline-autogel-for-treatment-of-carcinoid-syndrome-idUSFWN1Q30YU", "country": "US", "domain_rank": 408, "title": "Ipsen Biopharmaceuticals Canada Says Health Canada Approved Somatuline Autogel For Treatment Of Carcinoid Syndrome", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.845, "site_type": "news", "published": "2018-02-13T20:43:00.000+02:00", "replies_count": 0, "uuid": "48628716ab2cba3963c880fa6cca757517e434a1"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-ipsen-biopharmaceuticals-canada-sa/brief-ipsen-biopharmaceuticals-canada-says-health-canada-approved-somatuline-autogel-for-treatment-of-carcinoid-syndrome-idUSFWN1Q30YU", "ord_in_thread": 0, "title": "Ipsen Biopharmaceuticals Canada Says Health Canada Approved Somatuline Autogel For Treatment Of Carcinoid Syndrome", "locations": [], "entities": {"persons": [{"name": "ipsen", "sentiment": "negative"}, {"name": "ipsen sa", "sentiment": "negative"}], "locations": [{"name": "canada", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "ipsen biopharmaceuticals canada says health canada approved somatuline autogel", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 13 (Reuters) - Ipsen Sa:\n* IPSEN BIOPHARMACEUTICALS CANADA SAYS HEALTH CANADA APPROVES SOMATULINE AUTOGEL (LANREOTIDE INJECTION) 120 MG FOR TREATMENT OF CARCINOID SYNDROME Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-13T20:43:00.000+02:00", "crawled": "2018-02-14T12:16:30.001+02:00", "highlightTitle": ""}